KẾT QUẢ ĐIỀU TRỊ UNG THƯ BIỂU MÔ BUỒNG TRỨNG GIAI ĐOẠN IIIB-IIIC BẰNG PHÁC ĐỒ PACLITAXEL – CARBOPLATIN KẾT HỢP BEVACIZUMAB TẠI BỆNH VIỆN K

Abstract

Objective: Evaluation of some clinical and paraclinical characteristics of patients with stage IIIB-IIIC ovarian epithelial cancer treated with the paclitaxel-carboplatin regimen combined with Bevacizumab, progression-free survival of the study patient group. Method: This is a retrospective descriptive study with longitudinal follow-up. The study subjects were 39 patients with stage IIIB-IIIC ovarian epithelial cancer (EOC) treated with the paclitaxel-carboplatin regimen combined with Bevacizumab at National Cancer Hospital  from January 2020 to April 2023. Results: The average age of patients with stage IIIB-IIIC EOC is 53 years old, most of them present with hypogastric pain Clinical examinations often lack specific symptoms. Imaging diagnostics usually reveal multiple tumors of mixed nature accompanied by suggestive signs of malignancy. The CA12-5 concentration is markedly elevated in most cases, with the histological subtype of serous carcinoma being dominant. Stage IIIC accounts for the majority within the study group. The progression-free survival time reaches 26 ± 3.6 months with the Paclitaxel-Carboplatin regimen combined with Bevacizumab for the treatment of this patient cohort. There is no difference in treatment outcomes when comparing various factors such as age groups, disease stages, histopathological subtypes, and Bevacizumab dosage. Conclusions: The Paclitaxel-Carboplatin regimen combined with Bevacizumab demonstrates high effectiveness in treating patients with stage IIIB-IIIC ovarian epithelial cancer.